MTOR H1968Y

CI-VAR-00001916Explore in graph →NP_004949.1:p.His1968TyrNM_004958.3:c.5902C>TClinVar 376357 CIViC 283

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma2
MTOR H1968Y	Capivasertib	Predictive	D	Supports Sensitivity Response	3	rejected	EID721 In a cell line with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth. PMID 26490311 · Kong et al., 2016 · Open in CIViC	civic
MTOR H1968Y	Capivasertib + PI3K/BET Inhibitor LY294002Substitutes	Predictive	D	Supports Sensitivity Response	3	accepted	EID713 In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth. PMID 26490311 · Kong et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.